1. Home
  2. VYGR
  3. VYGR News

Latest Voyager Therapeutics Inc. (VYGR) News on November 28, 2025

We're A Little Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Rate
VYGR

Simply Wall St.

4 days ago

We're A Little Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Rate

VYGR

MT Newswires

17 days ago

Voyager Therapeutics Enters Collaboration With Transition Bio on ALS, FTD Drug Discovery

Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates
VYGR

Zacks

18 days ago

Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates

VYGR

Associated Press Finance

18 days ago

Voyager Therapeutics: Q3 Earnings Snapshot

Voyager Reports Third Quarter 2025 Financial and Operating Results
VYGR

GlobeNewswire

18 days ago

Voyager Reports Third Quarter 2025 Financial and Operating Results

Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
VYGR

GlobeNewswire

18 days ago

Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia

Moderna (MRNA) Reports Q3 Loss, Tops Revenue Estimates
VYGR

Zacks

22 days ago

Moderna (MRNA) Reports Q3 Loss, Tops Revenue Estimates

Voyager Therapeutics (VYGR) Soars 11.6%: Is Further Upside Left in the Stock?
VYGR

Zacks

2 months ago

Voyager Therapeutics (VYGR) Soars 11.6%: Is Further Upside Left in the Stock?

VYGR

MT Newswires

4 months ago

Sector Update: Health Care Stocks Climb Late Afternoon

VYGR

MT Newswires

4 months ago

Sector Update: Health Care

VYGR

MT Newswires

4 months ago

Voyager Therapeutics Introduces New Program Targeting Genetic Risk Factor of Alzheimer's Disease

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
VYGR

GlobeNewswire

4 months ago

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
VYGR

GlobeNewswire

6 months ago

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy’ Stocks
VYGR

TipRanks

6 months ago

Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy’ Stocks

With 46% ownership, Voyager Therapeutics, Inc. (NASDAQ:VYGR) has piqued the interest of institutional investors
VYGR

Simply Wall St.

6 months ago

With 46% ownership, Voyager Therapeutics, Inc. (NASDAQ:VYGR) has piqued the interest of institutional investors

Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication
VYGR

GlobeNewswire

6 months ago

Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication

Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates
VYGR

Zacks

7 months ago

Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates

Voyager Reports First Quarter 2025 Financial and Operating Results
VYGR

GlobeNewswire

7 months ago

Voyager Reports First Quarter 2025 Financial and Operating Results

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting
VYGR

GlobeNewswire

7 months ago

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting

Voyager Therapeutics Inc (VYGR) Q4 2024 Earnings Call Highlights: Strong Financial Position and ...
VYGR

GuruFocus.com

7 months ago

Voyager Therapeutics Inc (VYGR) Q4 2024 Earnings Call Highlights: Strong Financial Position and ...

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025
VYGR

GlobeNewswire

8 months ago

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

VYGR

Thomson Reuters StreetEvents

9 months ago

Q4 2024 Voyager Therapeutics Inc Earnings Call

Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates
VYGR

Zacks

9 months ago

Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates

VYGR

Associated Press Finance

9 months ago

Voyager Therapeutics: Q4 Earnings Snapshot

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
VYGR

GlobeNewswire

9 months ago

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast
VYGR

GlobeNewswire

9 months ago

Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach
VYGR

Pharma Voice

9 months ago

New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach

VYGR

MT Newswires

9 months ago

Voyager Therapeutics Reports Positive Trial Results From Alzheimer's Disease Treatment

Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease
VYGR

GlobeNewswire

9 months ago

Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
VYGR

GlobeNewswire

9 months ago

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

Voyager Therapeutics, Inc. (VYGR): A Cheap Biotech Stock to Invest In Now
VYGR

Insider Monkey

10 months ago

Voyager Therapeutics, Inc. (VYGR): A Cheap Biotech Stock to Invest In Now

VYGR

MT Newswires

10 months ago

Wedbush Adjusts Price Target on Voyager Therapeutics to $9 From $11, Maintains Outperform Rating

VYGR

MT Newswires

10 months ago

Voyager Therapeutics Shares Fall After Dropping Plan for VY9323 IND Filing in Mid-2025

Voyager Provides Update on SOD1 ALS Gene Therapy Program
VYGR

GlobeNewswire

10 months ago

Voyager Provides Update on SOD1 ALS Gene Therapy Program

Voyager to Present at Oppenheimer 25th Annual Healthcare Life Sciences Conference
VYGR

GlobeNewswire

10 months ago

Voyager to Present at Oppenheimer 25th Annual Healthcare Life Sciences Conference

What Makes Voyager Therapeutics (VYGR) a New Buy Stock
VYGR

Zacks

10 months ago

What Makes Voyager Therapeutics (VYGR) a New Buy Stock

VYGR

MT Newswires

a year ago

Cantor Fitzgerald Initiates Voyager Therapeutics at Overweight

Voyager Therapeutics, Inc. (VYGR): Is This Gene Therapy Stock a Good Buy Right Now?
VYGR

Insider Monkey

a year ago

Voyager Therapeutics, Inc. (VYGR): Is This Gene Therapy Stock a Good Buy Right Now?

3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
VYGR

Zacks

a year ago

3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025

Institutional investors own a significant stake of 48% in Voyager Therapeutics, Inc. (NASDAQ:VYGR)
VYGR

Simply Wall St.

a year ago

Institutional investors own a significant stake of 48% in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Wall Street Analysts See a 152.53% Upside in Voyager Therapeutics (VYGR): Can the Stock Really Move This High?
VYGR

Zacks

a year ago

Wall Street Analysts See a 152.53% Upside in Voyager Therapeutics (VYGR): Can the Stock Really Move This High?

Wedbush upgrades Voyager to Outperform on pipeline progress
VYGR

TipRanks

a year ago

Wedbush upgrades Voyager to Outperform on pipeline progress

VYGR

MT Newswires

a year ago

Wedbush Upgrades Voyager Therapeutics to Outperform From Neutral, Raises Price Target to $11 From $7

VYGR

MT Newswires

a year ago

Voyager Therapeutics Selects Development Candidate for Tau Silencing Program in Alzheimer's Disease

Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease
VYGR

GlobeNewswire

a year ago

Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease

Declining Stock and Decent Financials: Is The Market Wrong About Voyager Therapeutics, Inc. (NASDAQ:VYGR)?
VYGR

Simply Wall St.

a year ago

Declining Stock and Decent Financials: Is The Market Wrong About Voyager Therapeutics, Inc. (NASDAQ:VYGR)?

VYGR

Thomson Reuters StreetEvents

a year ago

Q3 2024 Voyager Therapeutics Inc Earnings Call

Voyager Therapeutics Inc (VYGR) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...
VYGR

GuruFocus.com

a year ago

Voyager Therapeutics Inc (VYGR) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...

Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates
VYGR

Zacks

a year ago

Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates

VYGR

Associated Press Finance

a year ago

Voyager Therapeutics: Q3 Earnings Snapshot

Voyager Reports Third Quarter 2024 Financial and Operating Results
VYGR

GlobeNewswire

a year ago

Voyager Reports Third Quarter 2024 Financial and Operating Results

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
VYGR

GlobeNewswire

a year ago

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
VYGR

GlobeNewswire

a year ago

Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
VYGR

Zacks

a year ago

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
VYGR

Zacks

a year ago

Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

VYGR

MT Newswires

a year ago

Leerink Partners Initiates Voyager Therapeutics at Outperform With $15 Price Target

Investing in Voyager Therapeutics (NASDAQ:VYGR) three years ago would have delivered you a 58% gain
VYGR

Simply Wall St.

a year ago

Investing in Voyager Therapeutics (NASDAQ:VYGR) three years ago would have delivered you a 58% gain

Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock?
VYGR

Zacks

a year ago

Bicycle Therapeutics (BCYC) Soars 5.7%: Is Further Upside Left in the Stock?

Strength Seen in Voyager Therapeutics (VYGR): Can Its 17.5% Jump Turn into More Strength?
VYGR

Zacks

a year ago

Strength Seen in Voyager Therapeutics (VYGR): Can Its 17.5% Jump Turn into More Strength?

VYGR

MT Newswires

a year ago

Voyager Therapeutics Says Third Gene Therapy Development Candidate Selected Under Neurocrine Collaboration

Voyager Advances Collaboration with Neurocrine; Third Gene Therapy Development Candidate Selected
VYGR

GlobeNewswire

a year ago

Voyager Advances Collaboration with Neurocrine; Third Gene Therapy Development Candidate Selected

Novartis to License VYGR's Capsid for Gene Therapy in Neurology
VYGR

Zacks

a year ago

Novartis to License VYGR's Capsid for Gene Therapy in Neurology

VYGR

MT Newswires

a year ago

Voyager Therapeutics Gets Capsid License for Gene Therapy Program From Novartis

Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
VYGR

GlobeNewswire

a year ago

Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VYGR

GlobeNewswire

a year ago

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
VYGR

GlobeNewswire

a year ago

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
VYGR

Simply Wall St.

a year ago

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
VYGR

GlobeNewswire

a year ago

Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates
VYGR

Zacks

a year ago

Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates

VYGR

Associated Press Finance

a year ago

Voyager Therapeutics: Q2 Earnings Snapshot

Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results
VYGR

GlobeNewswire

a year ago

Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results

Voyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
VYGR

GlobeNewswire

a year ago

Voyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VYGR

GlobeNewswire

a year ago

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VYGR

GlobeNewswire

a year ago

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Voyager Therapeutics, Inc. (NASDAQ:VYGR) is definitely on the radar of institutional investors who own 49% of the company
VYGR

Simply Wall St.

a year ago

Voyager Therapeutics, Inc. (NASDAQ:VYGR) is definitely on the radar of institutional investors who own 49% of the company

Voyager Therapeutics to Present at Multiple Virtual Investor Conferences
VYGR

GlobeNewswire

a year ago

Voyager Therapeutics to Present at Multiple Virtual Investor Conferences

VYGR

MT Newswires

a year ago

Voyager Therapeutics Names Nathan Jorgensen as Finance Chief

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer
VYGR

GlobeNewswire

a year ago

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
VYGR

GOBankingRates

a year ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

Bumrah delivers as India beat Pakistan in low-scoring thriller
VYGR

AFP

a year ago

Bumrah delivers as India beat Pakistan in low-scoring thriller

Italy beat Bosnia in final Euros warm-up
VYGR

AFP

a year ago

Italy beat Bosnia in final Euros warm-up

Trump loyalists proud to support 'felon' at Las Vegas rally
VYGR

AFP

a year ago

Trump loyalists proud to support 'felon' at Las Vegas rally

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
VYGR

Business Insider

a year ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

The Best Woody Perfume For Women
VYGR

Insider Monkey

a year ago

The Best Woody Perfume For Women

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase
VYGR

Reuters

a year ago

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

VYGR

Insider Monkey

a year ago

Best Date Night Fragrance in 2024

Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease
VYGR

GlobeNewswire

2 years ago

Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease

VYGR

Thomson Reuters StreetEvents

2 years ago

Q1 2024 Voyager Therapeutics Inc Earnings Call

VYGR

MT Newswires

2 years ago

Wedbush Adjusts Voyager Therapeutics' PT to $8 From $10, Keeps Neutral Rating

VYGR

GuruFocus.com

2 years ago

Voyager Therapeutics Inc (VYGR) Q1 2024 Earnings Call Transcript Highlights: Strategic ...

Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates
VYGR

Zacks

2 years ago

Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates

VYGR

Associated Press Finance

2 years ago

Voyager Therapeutics: Q1 Earnings Snapshot

Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
VYGR

GlobeNewswire

2 years ago

Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results

Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
VYGR

GlobeNewswire

2 years ago

Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

Voyager Therapeutics' (NASDAQ:VYGR) three-year earnings growth trails the splendid shareholder returns
VYGR

Simply Wall St.

2 years ago

Voyager Therapeutics' (NASDAQ:VYGR) three-year earnings growth trails the splendid shareholder returns

Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast
VYGR

GlobeNewswire

2 years ago

Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast

Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
VYGR

Zacks

2 years ago

Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates

Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates
VYGR

Zacks

2 years ago

Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
VYGR

GlobeNewswire

2 years ago

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment
VYGR

GlobeNewswire

2 years ago

Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

Share on Social Networks: